

Forschungsprojekte 2020

Projets de recherche 2020

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Grundlagenforschung / Recherche fondamentale			
<u>Gesuchsteller/In</u>	<u>Projektnummer</u> <u>Projekttitel</u>	<u>Dauer</u> <u>(Monate)</u>	<u>Betrag</u> <u>(CHF)</u>
<u>Candidat/e</u>	<u>Numéro du projet</u> <u>Titre du projet</u>	<u>Durée</u> <u>(mois)</u>	<u>Montant</u> <u>(CHF)</u>
Beer Hans-Dietmar , PD Dr. Dermatologische Klinik UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS-5087-08-2020 A novel role of p62 in skin cancer	12	82 550.–
Boyman Onur , Prof. Department of Immunology University Hospital Zurich (USZ) 8091 Zurich	KFS 5028-02-2020 The role of interleukin-2 in tumour immunoediting and immunotherapy	36	375 000.–
Cafilisch Amedeo , Prof. Biochemistry University of Zurich (UZH) 8057 Zurich	KFS 5016-02-2020 Targeting the m6A-RNA epitranscriptomic mark as a novel therapy for blood cancer	36	359 950.–
Collart Martine , Dr Microbiology and Molecular Medicine University of Geneva 1211 Geneva	KFS 5007-02-2020 Understand how the FKBP10 peptidyl-prolyl- cis-trans isomerase is essential for growth of lung cancer cells	36	375 000.–
Correia Bruno , Prof. Laboratoire de conception de protéines et d'immuno-ingénierie Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 5032-02-2020 Rational design of CAR-T-cells with improved safety and efficacy	36	365 200.–
D'Angelo Giovanni , Prof. Institute of Bioengineering Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4999-02-2020 Pharmacological targeting of the golgi localized oncoprotein GOLPH3	48	328 950.–

Derré Laurent , Dr Service d'urologie Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5105-08-2020 Unravelling bladder tumour immunity to define new treatments and predictive tools	24	185 600.–
Driessen Christoph , Prof. Dr. med. Abteilung Onkologie und Hämatologie Kantonsspital St. Gallen (KSSG) 9007 St. Gallen	KFS 4990-02-2020 The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo	42	357 150.–
Gfeller David , Prof. Ludwig Institute for Cancer Research University of Lausanne 1011 Lausanne	KFS 4961-02-2020 Robust analysis and prediction of T-cell epitopes in cancer	36	361 750.–
Grassi Fabio , MD, PhD Immunology Institute for Research in Biomedicine (IRB) 6500 Bellinzona	KFS 5033-02-2020 Intestinal ecosystem conditioning to improve the outcome of cancer immunotherapy with checkpoint inhibitors	24	250 000.–
Guarda Greta , Prof. Institute for Research in Biomedicine Università della Svizzera italiana 6500 Bellinzona	KFS 5141-08-2020 Targeting metabolic rewiring in cancers with altered RFX7	36	305 500.–
Hugues Stephanie , Prof. Pathology and Immunology Université de Genève (UNIGE) 1211 Genève	KFS 5108-08-2020 Impact of lymphatic vessel derived oxysterols on anti-tumour immunity and immunotherapy	48	340 650.–
Konstantinidou Georgia , SNF Prof. Institute of Pharmacology University of Bern 3010 Bern	KFS 5115-08-2020 Mechanisms of adaptation of KRAS-induced pancreatic tumours to hypoxia	36	370 900.–
Kruithof-de Julio Marianna , PD Dr. Urology University of Bern 3008 Bern	KFS 4960-02-2020 The role of lipid metabolism and fat in metastatic prostate cancer	36	348 700.–
Lutolf Matthias , Prof. EPFL - SV - IBI - LSCB Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 5103-08-2020 Dissecting the complex crosstalk within the colorectal cancer microenvironment through patient-derived tumouroids-on-chips	36	375 000.–

Martinou Jean-Claude , Prof. Département de biologie cellulaire (BICEL) Université de Genève (UNIGE) 1211 Genève	KFS 5022-02-2020 Assessing therapeutic effects in lung and pleural cancers	12	122 950.–
Meraldi Patrick , Prof. Dr. Faculty of Medicine University of Geneva 1211 Geneva	KFS 5117-08-2020 Targeting multipolar spindles in cancer cells with a synergistic drug combination	48	346 650.–
Münz Christian , Prof. Institut für Experimentelle Immunologie Universität Zürich (UZH) 8057 Zürich	KFS 4962-02-2020 The contribution of early lytic replication of oncogenic gamma-herpesviruses to lymphoma formation and its immunotherapeutic targeting	36	369 000.–
Oricchio Elisa , Prof. ISREC-SV Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 5102-08-2020 Define how aberrant cathepsin S activity modifies the tumour microenvironment and explore new therapeutic avenues	48	329 400.–
Ruiz i Altaba Ariel , Prof. Faculté de médecine Université de Genève (UNIGE) 1211 Genève	KFS 4965-02-2020 Apoptosis-surviving cells as an origin of metastases	36	373 050.–
Scheuermann Jörg , PD Dr. Chemistry and Applied Biosciences ETH Zurich 8093 Zurich	KFS 5012-02-2020 Next-generation targeted small molecule- drug conjugates (SMDCs) from DNA- encoded chemical libraries	36	243 900.–
Schottelius Margret , Prof. Translational Radiopharmaceutical Sciences Centre hospitalier universitaire vaudois (CHUV) 1011 Lausanne	KFS 5123-08-2020 RADIATION: RAdiolabeled DIAbodies for Targeted Imaging in ONcology - establishment of a one-step 18F-labeling platform for the generation of versatile diabody-based tracers	36	306 150.–
Sendoel Ataman , Prof. Institute for Regenerative Medicine University of Zurich (UZH) 8952 Schlieren-Zurich	KFS 5023-02-2020 Tackling the role of small open reading frames in cancer	36	371 150.–
Theurillat Jean-Philippe , Prof. Dr. Institute of Oncology Research (IOR) 6500 Bellinzona	KFS 5136-08-2020 Loss and revival of androgen receptor signalling in advanced prostate cancer	36	273 600.–

Thomä Nicolas , Prof. Dr. Department Growth Control Friedrich Miescher Institut für biomedizinische Forschung (FMI) 4058 Basel	KFS 4980-02-2020 Harnessing a new mechanism for kinase inactivation in cancer therapy	36	374 900.–
Trono Didier , Prof. Global Health Institute Ecole Polytechnique Fédérale de Lausanne (EPFL) 1015 Lausanne	KFS 4968-02-2020 POU5F1B as new oncogene and therapeutic target	36	373 550.–
van den Broek Maries , Prof. Dr. Institute of Experimental Immunology University of Zurich 8057 Zurich	KFS 5104-08-2020 Control of liver metastasis by conventional NK cells and tissue-resident ILC1s	48	328 000.–
Vannini Nicola , Dr Ludwig Institute for Cancer Research University of Lausanne (UNIL) 1066 Epalinges	KFS 4993-02-2020 Application of NAD-boosting strategies in cancer immunotherapy	36	361 750.–
Vetter Marcus , PD Dr. med. Medical Oncology Basel University Hospital 4031 Basel	KFS 5140-08-2020 Personalized treatment for patients with estrogen receptor alpha-positive metastatic breast cancer: anticipating and targeting resistance to CDK4/6 inhibitors	36	358 050.–
Weber Achim , Prof. Dr. Institut für Pathologie und Molekularpathologie UniversitätsSpital Zürich (USZ) 8091 Zürich	KFS 5121-08-2020 Characterization of non-canonical open reading frames in hepatocellular carcinoma	36	374 800.–

Klinische Forschung / Recherche clinique			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Frattini Milo , Dr Molecular Pathology Istituto cantonale di patologia 6601 Locarno	KFS 5133-08-2020 Proof-of-concept study using ctDNA for treatment adaption of patients with advanced NSCLC with PD-L1 \geq 50% receiving first-line pembrolizumab	48	319 700.–
Le Magnen Clementine , Dr Institute of Pathology University Hospital Basel 4031 Basel	KFS 4983-02-2020 Multidimensional imaging of patient-derived organoids: towards advancing models of urological cancers for personalized medicine	36	241 000.–
Lugli Alessandro , Prof. Dr. med. Institute of Pathology University of Bern 3008 Bern	KFS 5114-08-2020 Tumour budding in colon cancer: tumour buds profile in different tumour microenvironments of the colonic wall	36	331 500.–
Piscuoglio Salvatore , Dr. Department of Biomedicine University of Basel 4031 Basel	KFS 4988-02-2020 Augmenting precision medicine for colorectal cancer patients with ex-vivo drug screening	30	234 400.–
Reyes Mauricio , Prof. Dr Insel Data Science Center University of Bern 3008 Bern	KFS 5127-08-2020 Artificial intelligence for Automated Quality Assurance in RadioTherapy for glioblastoma target volume and organs at risk delineation in clinical trials - AQUA RT	48	355 050.–
Rubin Mark A. , Prof. Dr. med. Department for BioMedical Research (DBMR), University of Bern 3008 Bern	KFS 4982-02-2020 Towards a new taxonomy for advanced prostate cancer	36	374 750.–
Streckmann Fiona , Dr. Department of Sport, Exercise and Health University of Basel 4052 Basel	KFS 5145-08-2020 Preventing sensory and motor dysfunctions in children receiving neurotoxic chemotherapy - a randomized controlled, multi-centre trial	48	374 200.–
von Gunten Stephan , Prof. Dr. Institut für Pharmakologie Universität Bern 3010 Bern	KFS 4958-02-2020 Tumour glycosylation as immune checkpoint for cytotoxic lymphocytes	36.	373 250.–
Weber Walter Paul , Prof. Dr. med. Surgery University Hospital Basel 4031 Basel	KFS 4991-02-2020 Impact of pre- versus sub-pectoral implant-based breast reconstruction on oncological safety	48	150 150.–

Psychosoziale Forschung / Recherche psychosociale			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Kobleder Andrea , Prof. Dr. phil. Nursing Science University of Applied Science St. Gallen 9000 St.Gallen	KFS 5113-08-2020 Trust, interprofessional collaboration and the role of the APN in the treatment pathway of women with gynaecological cancer – a mixed methods study (TANGO-Study)	28	210 550.–
Michel Gisela , Prof. Health Sciences and Medicine University of Lucerne 6002 Lucerne	KFS 4995-02-2020 Needs, desires and psychosocial outcomes in bereaved parents who lost their child to cancer: palliative and end-of-life care in paediatric oncology	36	355 100.–

Epidemiologische Forschung / Recherche épidémiologie			
Gesuchsteller/In	Projektnummer Projekttitel	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bucher Heiner C. , Prof. Institut für klinische Epidemiologie & Biostatistik Universität Basel 4031 Basel	KFS 4981-02-2020 Measures of longitudinal immune dysfunction and risk of AIDS and non-AIDS defining malignancies in HIV-infected antiretroviral treated positive individuals	12	105 900.–
Misselwitz Benjamin , Prof. Dr. University Hospital for Visceral Surgery and Medicine Inselspital Bern 3010 Bern	KFS 5164-08-2020 Microsimulation for optimization of personalized colorectal cancer screening strategies considering patient history and genetics	36	366 900.–
Vokinger Kerstin Noëlle , Prof. Dr. med. et. Dr. iur. Institute of Law University of Zurich (UZH) 8001 Zurich	KFS 5031-02-2020 A comparative analysis of launch prices and price developments of cancer drugs in Switzerland, Germany, England, and the US	10	63 800.–
von der Weid Nicolas , Prof. Dr. med. Pediatric/Hematology/Oncology University Children's Hospital Basel (UKBB) 4031 Basel	KFS 5027-02-2020 Prospective multicentre cohort study for diagnosing cardiac dysfunction in Swiss childhood cancer survivors	36	336 950.–

Stipendien 2020

Bourses 2020

Unterstützt von: / Soutenus par:

krebsforschung schweiz
recherche suisse contre le cancer
ricerca svizzera contro il cancro
swiss cancer research

Gesuchsteller/In	Projektnummer Projekttitle	Dauer (Monate)	Betrag (CHF)
Candidat/e	Numéro du projet Titre du projet	Durée (mois)	Montant (CHF)
Bersier Ludivine , Dr Department of Oncology UNIL-CHUV University of Lausanne 1015 Lausanne	MD-PhD 5089-06-2020 SAMW MD-PhD Stipendium / Targeting chemoresistance and immune exclusion in colorectal cancer	36	191 553.–
Di Salvo Ivana , Dr Gynecology and Obstetrics University Hospital Basel 4031 Basel	BIL KFS 4986-02-2020 Improving cervical cancer screening in women living with HIV attending chronic disease clinics in semi-rural Tanzania Destination: Ifakara health institute and St. Francis Hospital, Ifakara, Tanzania	20	73 650.–
Furrer Marc Alain , Dr. med. Department of Urology Inselspital Bern 3010 Bern	BIL KFS 4989-02-2020 CAMUS (complication reporting after major urological surgeries) - a worldwide multicentric collaboration study: is the Bern comprehensive complication index applicable and valid in all major urological surgeries in order to reform complication reporting, and is there any room for improvement in perioperative morbidity and mortality? Destination: Department of Urology, Guy's Hospital, London, GB	12	72 700.–
Schmid Dominic Department of Biomedicine University of Basel 4031 Basel	MD-PhD 5090-06-2020 SAMW MD-PhD Stipendium / Mechanisms of T-cell dysfunction in human tumours	36	188 250.–
Zens Philipp Immanuel Institute of Pathology University of Bern 3018 Bern	MD-PhD 5088-06-2020 SAMW MD-PhD Stipendium / Molecular epidemiology of lung cancer brain metastases	36	189 902.–